Why the study?
Does sparse concentration sampling robustly capture the disposition of citalopram in clinical trial subjects?
Population
106 patients participating in 2 clinical trials, age 22-93 years
Design
Other
Authors
Loading...
Sparse sampling suffices for citalopram population PK modeling; extends efficient analysis to elderly and weight-diverse trial participants.
Does sparse concentration sampling robustly capture the disposition of citalopram in clinical trial subjects?
Hyper-sparse sampling designs (1-2 samples per subject) are adequate to support population pharmacokinetic analysis of citalopram, which is particularly valuable for elderly populations.
Bies et al. (2004) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: